American Society of Hirudotherapy

Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties

Review published in Cellular and molecular life sciences : CMLS (1997)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentSalivary PharmacologyHall et al. · Cellular and molecular life sciences : CMLS, 1997

Abstract

Thrombin is a serine proteinase that can interact with a large number of diverse macromolecular substrates, which results in either a procoagulant or anticoagulant effect. These divergent properties are physiologically regulated by the endogenous protein thrombomodulin. This review summarizes recent work on a variety of methods used to exploit the allosteric nature of the enzyme. The procoagulant and anticoagulant functions of thrombin can be modulated by sodium binding, site-directed mutagenesis, and a small synthetic molecule. Modulation of thrombin's intrinsic properties represents a novel approach to the development of unique antithrombotic agents.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAllosteric RegulationAnimalsAnticoagulantsAntithrombin IIIAntithrombinsFibrinolytic AgentsHumansProtein ConformationProtein EngineeringStructure-Activity RelationshipThrombinThrombomodulin

Summary

This review summarizes how thrombin's procoagulant and anticoagulant functions can be modulated through sodium binding, site-directed mutagenesis, and a small synthetic molecule, an allosteric strategy proposed for developing novel antithrombotic agents.

Context

This review discusses strategies for developing novel antithrombotic agents by exploiting thrombin's allosteric regulation, noting that thrombin's procoagulant and anticoagulant functions are physiologically regulated by thrombomodulin and can be modulated by sodium binding, site-directed mutagenesis, and a small synthetic molecule. It frames modulation of thrombin's intrinsic properties as a novel antithrombotic approach. The abstract does not mention hirudin, leeches, leech-derived compounds, or hirudotherapy.

Citation

Reference (Vancouver style)

Hall SW, Gibbs CS, Leung LL. Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties. Cell Mol Life Sci. 1997;53(9):731-736. doi:10.1007/s000180050092. PMID: 9368669

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.